Amicus Therapeutics Profit Margin

The latest profit margin for FOLD is -4.27% as of December 2025. That compares with 2.31% in the prior-year period — down 285.0% year over year. That is below the Healthcare sector average of 13.89%. Investors often review this figure alongside Amicus Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, FOLD's profit margin moved from 2.31% to -4.27% — a 285.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Amicus Therapeutics's valuation or profitability profile.

Against Healthcare companies, FOLD currently prints -4.27% for profit margin, while the sector average sits near 13.89%. That is roughly 130.8% below the sector mean. Large gaps often invite a closer look at Amicus Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Amicus Therapeutics converts resources into returns. At -4.27%, FOLD may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 2.31% in the prior-year period — down 285.0% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting FOLD's profit margin (-4.27%), review year-over-year change from 2.31%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.